Database Update: Pharmaceutical Drug Export from Russia (October 2017)
Between January and October 2017, Russia exported 16.7 bln RUB (customs paid) worth of pharmaceuticals (excluding EAEU countries), which is 2.2% lower than that of the same period of 2016. The exports in physical terms have risen by 5.4%, though, with 465.6 mln units of pharmaceuticals. The export line has been significantly expanded, with around 3,190 different trademarks.
The exports does not include only Russian drugs. Pharmaceuticals manufactured in Russia account for 64% of the export in monetary terms over the period, which is 1% higher than a year ago. Pharmaceuticals manufactured and imported from Germany come second, with 5.5% of the export, followed by Belarus, with 4%.
Pharmaceutical company Stada has the biggest share in the export, with 7.9%, followed by Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of Russian Academy of Sciences. The exports of the former have decreased by 33% in monetary terms over the year, while the exports of the latter have risen by 64%. Biocad showed the best progress, having increased the exports by 2.4 times.
As for pharmaceuticals, Yellow Fever Vaccine is the most exported drug, with Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of Russian Academy of Sciences having exported 1.3 bin RUB worth of it. As part of one of the Unicef programs, it has been exported to 38 countries, mostly Nigeria, Angola, and Congo.
Dynamics of pharmaceutical drug export from Russia, excluding EAEU countries (January – October 2016, January – October 2017)